Initial Statement of Beneficial Ownership (3)
March 21 2018 - 5:03PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Keefer Jason
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/9/2018
|
3. Issuer Name
and
Ticker or Trading Symbol
OSIRIS THERAPEUTICS, INC. [OSIR]
|
(Last)
(First)
(Middle)
7015 ALBERT EINSTEIN DRIVE
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
Interim President & CEO /
|
(Street)
COLUMBIA, MD 21046
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Incentive Stock Opton (right to buy)
|
7/19/2018
(1)
|
7/18/2027
|
Common Stock
|
16000
|
$6.80
|
D
|
|
Explanation of Responses:
|
(1)
|
4,000 shares underlying this option shall vest on each of July 19, 2018, July 19, 2019, July 19, 2020 and July 19, 2021, subject to Reporting Person's continued service through the applicable vesting date.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Keefer Jason
7015 ALBERT EINSTEIN DRIVE
COLUMBIA, MD 21046
|
|
|
Interim President & CEO
|
|
Signatures
|
/s/ Jason Keefer
|
|
3/21/2018
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Sep 2023 to Sep 2024